BioSpace News Archive

Beyond Air, Inc. announced financial results for its fiscal fourth quarter and year ended March 31, 2022.

StageZero Life Sciences, Ltd is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company’s management information circular dated May 12, 2022, at its annual and special meeting of shareholders held on June 28, 2022.

Labcorp (NYSE: LH), today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual European Academy of Allergy and Clinical Immunology (EAACI) Annual Scientific meeting, July 1 – 3, 2022, in Prague, Czech Republic.

CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), announces that phase 1b study results of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes have been published in Nature Communications.

Elevar Therapeutics, Inc., today announced the hiring of Jan M. Van Tornout, M.D., MSc., as chief medical officer, and Gordon Schooley, Ph.D., as chief regulatory officer.

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.

BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI).

Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications.